What Does Formycon AG Do?

Total employees192
HeadquartersPlanegg/Martinsried
Founded2012

Formycon is a leading, independent German developer of high-quality biosimilar drugs. The company focuses on therapies in ophthalmology, immunology, and other serious chronic diseases, with the mission to provide patients worldwide with access to affordable, life-enhancing medicines. Formycon leverages its extensive expertise in analytics, process development, and clinical research, along with strategic partnerships, to advance its robust pipeline of biosimilar candidates.

Where Is Formycon AG's Headquarters?

HQ Function

Serves as the central hub for Formycon's research and development, corporate governance, clinical trial management, and strategic business operations for its global biosimilar programs.

Notable Features:

State-of-the-art laboratory and office facilities situated within the renowned Martinsried biotech cluster, one of Europe's leading life science hubs, fostering collaboration and innovation.

Work Culture:

A dynamic, science-driven, and innovative environment that values expertise, collaboration, precision, and quality. Employees are typically passionate about contributing to medical advancements and improving patient access to affordable treatments.

HQ Significance:

The headquarters is pivotal for Formycon's mission, driving the development of its biosimilar pipeline and managing global partnerships. Its strategic location in the Martinsried biotech cluster provides access to top talent, research institutions, and industry networks.

Values Reflected in HQ: The headquarters' focus on cutting-edge research, high-quality development processes, and strategic collaboration reflects Formycon's commitment to innovation, scientific excellence, and its mission to provide affordable, high-quality medicines.

Location:

Formycon operates with a global outlook, primarily supporting its worldwide mission through a network of international partners for clinical development, manufacturing, and commercialization of its biosimilar candidates. While its core research and development activities are centralized at its German headquarters, Formycon's products are intended for global markets, including Europe, North America, and other key regions, to ensure broad patient access to its therapies.

Street Address:

Fraunhoferstraße 22

City:

Planegg/Martinsried

State/Province:

Bavaria

Country:

Germany

Where Else Does Formycon AG Operate Around the World?

Planegg/Martinsried, Bavaria/Germany

Address: Lochhamer Str. 15, 82152 Planegg/Martinsried, Germany

Strengthens Formycon's development pipeline and operational capacity within the German biotech ecosystem, focusing on specialized aspects of biosimilar development and potentially market strategies.

Buying Intent Signals for Formycon AG

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Formycon AG? Meet the Executive Team

As of April 2025, Formycon AG' leadership includes:

Dr. Stefan Glombitza - Chief Executive Officer (CEO)
Enno Spillner - Chief Financial Officer (CFO)
Nicola Mikulcik - Chief Business Officer (CBO)
Dr. Andreas Seidl - Chief Scientific Officer (CSO)

Who's Investing in Formycon AG?

Formycon AG has been backed by several prominent investors over the years, including:

Athos Service GmbH (Strüngmann family)
Active Ownership Fund SICAV-FIS SCS
Wendeln Beiteiligungs und Verwaltungs GmbH

What Leadership Changes Has Formycon AG Seen Recently?

Hire4
Exits2

Formycon significantly reshaped its executive team over the past 12-18 months, appointing a new CEO (via internal role change to sole CEO), CFO, CBO, and CSO. These changes are aimed at steering the company through its next phase of growth, development, and commercialization of its biosimilar pipeline.

Departures

Dr. Carsten Brockmeyer, Dr. Carsten Brockmeyer, co-founder and former CEO, left the Management Board and transitioned to an advisory role.
Dr. Nicolas Combé, Dr. Nicolas Combé departed his role as Chief Financial Officer.

New Appointments:

Dr. Stefan Glombitza, Dr. Stefan Glombitza appointed sole Chief Executive Officer, previously served as Co-CEO.
Enno Spillner, Enno Spillner joined Formycon as the new Chief Financial Officer.
Nicola Mikulcik, Nicola Mikulcik appointed as Formycon's Chief Business Officer.
Dr. Andreas Seidl, Dr. Andreas Seidl appointed as Formycon's Chief Scientific Officer.

What Technology (Tech Stack) Is Used byFormycon AG?

Discover the tools Formycon AG uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Formycon AG Email Formats and Examples

Formycon AG commonly uses the 'firstname.lastname@formycon.com' email format for its employees. This is a standard pattern for many German and European companies.

firstname.lastname@formycon.com

Format

stefan.glombitza@formycon.com

Example

85%

Success rate

What's the Latest News About Formycon AG?

formycon.comMay 23, 2024

Formycon and Fresenius Kabi Announce Launch of FYB201 (Ranibizumab), a Biosimilar to Lucentis®, in Canada

Formycon and its commercialization partner Fresenius Kabi announced the launch of FYB201 (ranibizumab), a biosimilar to Lucentis®, in Canada for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME)....more

formycon.comApril 25, 2024

Formycon Reports Successful 2023 Financial Year and Provides Outlook for 2024

Formycon AG reported a successful fiscal year 2023 with significant progress in its biosimilar pipeline and positive financial results. The company provided an optimistic outlook for 2024, expecting further revenue growth from product commercialization and milestone payments....more

formycon.comOctober 26, 2023

Formycon Strengthens Management Board: Nicola Mikulcik Appointed Chief Business Officer and Dr. Andreas Seidl Chief Scientific Officer

Formycon AG announced the expansion of its Management Board with the appointment of Nicola Mikulcik as Chief Business Officer (CBO) and Dr. Andreas Seidl as Chief Scientific Officer (CSO), effective November 1, 2023, to support the company's growth strategy....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Formycon AG, are just a search away.